Valneva's Zika vaccine candidate – VLA1601

Zika is a mosquito-borne disease associated with birth defects

The most common symptoms of Zika virus infection are mild fever, skin rash and conjunctivitis (pink eye) lasting between two to seven days. Global health officials are alarmed because of its link to brain defects in infants as well as the rare Guillain-Barré syndrome that can lead to paralysis.

In November 2018, Valneva and Emergent BioSolutions Inc. reported positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika virus (see press release).

The Phase 1 study was designed to assess safety and immunogenicity. It is being co-financed by Emergent and Valneva as part of an exclusive, worldwide license agreement signed in July 2017. The agreement includes pre-defined post-Phase 1 opt-in rights for Emergent. 


VLA1601 is a highly purified inactivated vaccine candidate against the Zika virus, developed using the same manufacturing platform as Valneva’s IXIARO® (JESPECT®) Japanese Encephalitis (“JE”) vaccine.

In pre-clinical development, VLA1601 demonstrated excellent purity and had an overall biological, chemical and physical profile comparable to the commercially produced JE vaccine. Valneva has an established manufacturing process in its dedicated clinical JE vaccine facility.

About Zika

PR Emergent BioSolutions and Valneva Report Positive Phase 1 Results for their Vaccine Candidate Against the Zika Virus
PR Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus
PR Valneva and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus
PR Valneva Announces Successful Generation of a Highly-purified Zika Vaccine Candidate Using its FDA-EMA Approved Japanese Encephalitis Platform
Please update your browser...